The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
A growing number of FDA employees are eyeing the exits as chaos and uncertainty sweep through the agency, according to ...
The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...
A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...
Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...
The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...
The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration, an alleged bribery scandal involving a ...
Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just ...
Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...
UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...
Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...
The weekend's chaos at the Food and Drug Administration is prompting questions around how much more the agency can take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback